Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Restructuring Costs (2022 - 2025)

Marimed (MRMD) has disclosed Restructuring Costs for 4 consecutive years, with $145000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Restructuring Costs fell 60.92% to $145000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $542000.0, a 36.46% decrease, with the full-year FY2024 number at $951000.0, up 36.83% from a year prior.
  • Restructuring Costs was $145000.0 for Q3 2025 at Marimed, up from $139000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $754000.0 in Q2 2022 to a low of $32000.0 in Q3 2023.
  • A 4-year average of $214500.0 and a median of $144000.0 in 2022 define the central range for Restructuring Costs.
  • Peak YoY movement for Restructuring Costs: plummeted 77.62% in 2023, then soared 1059.38% in 2024.
  • Marimed's Restructuring Costs stood at $64000.0 in 2022, then dropped by 25.0% to $48000.0 in 2023, then surged by 204.17% to $146000.0 in 2024, then fell by 0.68% to $145000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Restructuring Costs are $145000.0 (Q3 2025), $139000.0 (Q2 2025), and $112000.0 (Q1 2025).